ReviewThe Journal of clinical investigation2019
The supply chain of human pancreatic β cell lines.
Review in The Journal of clinical investigation, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 54 citations in OpenAlex.
- Pancreatic islets: new discoveries for innovative treatments of diabetes?Diabetologia · 2026Review
- Human donor islets coated with functionalized chitosan and alginate nanoscale layers can restore normoglycemia in diabetic mice.Materials today. Bio · 2026Article
- Pancreatic Ultrasound Features at Diagnosis of Type 1 Diabetes: Age-Related Differences in Children.Journal of clinical medicine · 2025Article
- Thymic Mimetic Cells: Evolutionarily Ancient Mirrors of the Periphery.Immunological reviews · 2025Review
- Scalability of spheroid-derived small extracellular vesicles production in stirred systems.Frontiers in bioengineering and biotechnology · 2025Article
- A mathematical model of insulin action on acinar tissue linking histology and radiological imaging of the pancreas.Frontiers in endocrinology · 2025Article
- Article
- Article
- Developmentally dynamic changes in DNA methylation in the human pancreas.BMC genomics · 2024Article
- Progress in experimental models to investigate the in vivo and in vitro antidiabetic activity of drugs.Animal models and experimental medicine · 2024Review
- Hydrogel-Encapsulated Pancreatic Islet Cells as a Promising Strategy for Diabetic Cell Therapy.Research (Washington, D.C.) · 2024Review
- Extracellular electrophysiology on clonal human β-cell spheroids.Frontiers in endocrinology · 2024Article
- Characterization of the functional and transcriptomic effects of pro-inflammatory cytokines on human EndoC-βH5 beta cells.Frontiers in endocrinology · 2023Article
- Screening of Metabolism-Disrupting Chemicals on Pancreatic α-Cells Using In Vitro Methods.International journal of molecular sciences · 2022Article
- DNA damage to β cells in culture recapitulates features of senescent β cells that accumulate in type 1 diabetes.Molecular metabolism · 2022Article
- Characterization of the Secretome, Transcriptome, and Proteome of Human β Cell Line EndoC-βH1.Molecular & cellular proteomics : MCP · 2022Article
- In Vitro Assays to Identify Metabolism-Disrupting Chemicals with Diabetogenic Activity in a Human Pancreatic β-Cell Model.International journal of molecular sciences · 2022Article
- Screening of Relevant Metabolism-Disrupting Chemicals on Pancreatic β-Cells: Evaluation of Murine and Human In Vitro Models.International journal of molecular sciences · 2022Article
- Article
- Stem Cell-Derived β Cells: A Versatile Research Platform to Interrogate the Genetic Basis of β Cell Dysfunction.International journal of molecular sciences · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients with type 1 or type 2 diabetes have an insufficiency in their functional β cell mass. To advance diabetes treatment and to work toward a cure, a better understanding of how to protect the pancreatic β cells against autoimmune or metabolic assaults (e.g., obesity, gestation) will be required. Over the past decades, β cell protection has been extensively investigated in rodents both in vivo and in vitro using isolated islets or rodent β cell lines. Transferring these rodent data to humans has long been challenging, at least partly for technical reasons: primary human islet preparations were scarce and functional human β cell lines were lacking. In 2011, we described a robust protocol of targeted oncogenesis in human fetal pancreas and produced the first functional human β cell line, and in subsequent years additional lines with specific traits. These cell lines are currently used by more than 150 academic and industrial laboratories worldwide. In this Review, we first explain how we developed the human β cell lines and why we think we succeeded where others, despite major efforts, did not. Next, we discuss the use of such functional human β cell lines and share some perspectives on their use to advance diabetes research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.